Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses post-finasteride syndrome, highlighting occasional adverse sexual and systemic effects in men and women, but reports no new research findings while emphasizing the need for better education about the drug's risks.

This study found a significant correlation between estradiol/testosterone imbalance and erectile dysfunction severity in Klinefelter syndrome patients, also highlighting high satisfaction with penile prosthesis in both psychogenic and organic cases.

This study found that longer exposure to 5α-reductase inhibitors significantly increased the risk of persistent erectile dysfunction, especially in younger men exposed to finasteride.

This review discusses the use of platelet-rich plasma injections for treating erectile dysfunction, noting the potential for regenerative medicine to reverse or halt disease progression, but it reports no new clinical results.

This study concluded that administering dutasteride for more than 8 weeks in rats could lead to irreversible erectile dysfunction, even after stopping the medication.

In this study, men using Propecia for alopecia showed normal erectile hemodynamics despite erectile dysfunction after stopping 5-alpha reductase inhibitors, while some BPH patients exhibited abnormal results potentially linked to vascular risk factors.

This study found that young men using finasteride for androgenic alopecia exhibited erectile tissue fibrosis and associated sexual dysfunction, including low libido and mood changes.

Long use of finasteride and dutasteride can cause long-term erection problems.

This study found that young men using finasteride for androgenic alopecia experienced erectile dysfunction and signs of erectile tissue fibrosis, alongside symptoms like low libido and mood changes.

This study found a positive association between erectile dysfunction and the functionality of the marital subsystem in patients with benign prostatic hyperplasia treated with tamsulosin and finasteride.

This review discusses the increasing prevalence of erectile dysfunction in young men and emphasizes the importance of identifying specific causes for effective management, reporting no new clinical results.

This study reviews the significant prevalence of organic etiologies, especially vascular causes, in erectile dysfunction among men under 40 and emphasizes thorough evaluation and consideration of treatment options like exercise and PDE-5 inhibitors.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

This review highlights that sexual dysfunction associated with 5-alpha-reductase inhibitors is recognized in clinical literature, with erectile dysfunction being the most common adverse effect, followed by ejaculatory dysfunction and decreased libido.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This study found that two injections of platelet-rich plasma were safe but no more effective than placebo in treating mild to moderate erectile dysfunction.

This review summarized existing research on finasteride and erectile dysfunction, finding a correlation between finasteride use for benign prostatic hyperplasia and ED, but not strongly for male androgenetic alopecia.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

This review examines the use of tadalafil and finasteride as a combined therapy for BPH, suggesting it may effectively reduce treatment-related sexual adverse events and improve symptom relief.

This study found no significant difference between alpha-blockers and finasteride in contributing to erectile dysfunction among men with other risk factors, with age and other underlying conditions being stronger influences.

This study highlights that shock wave therapy for erectile dysfunction is commonly performed by nonurologists in major U.S. metropolitan areas, with high costs and varied treatment protocols.

Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.

This review synthesizes evidence on the prevalence, impacts, causes, and treatment of erectile dysfunction in men under 40 but reports no new clinical results; the authors emphasize the need for comprehensive evaluation and individualized care.

This study analyzed data from the FDA Adverse Event Reporting System and found that finasteride had the highest reporting frequency and signal strength for drug-induced erectile dysfunction among 734 drugs, with compound preparations posing higher risks than single ingredients.

This case report suggests a potential link between the intake of Serenoa repens, commonly known as Saw palmetto, and the onset of erectile dysfunction.

This study found that young men with post-finasteride syndrome may experience erectile dysfunction due to potential histologic changes in penile tissue, despite having normal penile Doppler hemodynamics.

This abstract is a website placeholder and reports no research findings or results; it contains navigation and policy information for JAMA Dermatology.

In this large retrospective study, low-dose finasteride for androgenetic alopecia was associated with an increased risk of erectile dysfunction at one and three years among men aged 18-45.

This study described the population-level incidence of erectile dysfunction in men using finasteride for androgenetic alopecia, finding a varied risk that highlights the complexity of interpreting sexual side effects.